VCEL Q4 2024 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena

VCELVericel Corporation

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$75M+16.0% YoY

Gross Profit

$58M77.6% margin

Operating Income

$18M24.5% margin

Net Income

$20M26.3% margin

EPS (Diluted)

$0.38

QoQ Revenue Growth

+30.2%

Cash Flow

Operating Cash Flow

$22M

Free Cash Flow

$8M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$433M

Total Liabilities

$141M

Stockholders' Equity

$292M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75M	$65M	+16.0%
Gross Profit	$58M	$49M	+20.6%
Operating Income	$18M	$13M	+45.1%
Net Income	$20M	$13M	+52.4%

Revenue Segments

MACI Implants And Kits

$68M100%